Kondoh Masuo, Nagashima Fumihiro, Suzuki Ikue, Harada Motoki, Fujii Makiko, Asakawa Yoshinori, Watanabe Yoshiteru
Department of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Machida, Tokyo, Japan.
Planta Med. 2005 Nov;71(11):1005-9. doi: 10.1055/s-2005-873133.
Some diterpenoids show various biological activities, including anti-inflammatory, anti-HIV and anti-tumor activity. Previously, we have focused our research on the apoptosis-inducing properties of diterpenoids and found that some ent-kaurene-type diterpenoids induced apoptosis in human leukemia HL-60 cells. In this study, we have investigated the induction of apoptosis in HL-60 cells by the novel ent-kaurene-type diterpenoids, jungermannenones A (JA), B (JB), C (JC) and D (JD), isolated from the New Zealand liverwort Jungermannia species. Treatment of the cells with each compound for 12 h resulted in cytotoxicity (IC (50) values: A, 1.3; B, 5.3; C, 7.8; D, 2.7 microM) and caused DNA fragmentation and nuclear condensation, both biochemical markers of the induction of apoptosis. Treatment with the compounds resulted in activation of caspases, including caspase-3 and caspase-8. A broad-spectrum inhibitor of caspases, Z-Asp-CH (2)-DCB, attenuated the cytotoxicity induced by these compounds, suggesting that JA, JB, JC and JD induced apoptosis through a caspase-dependent pathway. JA and JD inhibited the activity of nuclear factor-kappaB, which is a transcriptional factor of anti-apoptotic factors. Thus, some of these new ent-kaurene-type diterpenoids may be promising candidates for anti-tumor agents.
一些二萜类化合物具有多种生物活性,包括抗炎、抗HIV和抗肿瘤活性。此前,我们的研究重点是二萜类化合物的诱导凋亡特性,并发现一些对映贝壳杉烯型二萜类化合物可诱导人白血病HL-60细胞凋亡。在本研究中,我们研究了从新西兰叶苔属植物中分离出的新型对映贝壳杉烯型二萜类化合物——耳叶苔烯酮A(JA)、B(JB)、C(JC)和D(JD)对HL-60细胞凋亡的诱导作用。用每种化合物处理细胞12小时会导致细胞毒性(IC(50)值:A为1.3;B为5.3;C为7.8;D为2.7微摩尔),并引起DNA片段化和核浓缩,这两者都是凋亡诱导的生化标志物。用这些化合物处理会导致半胱天冬酶激活,包括半胱天冬酶-3和半胱天冬酶-8。一种广谱半胱天冬酶抑制剂Z-Asp-CH(2)-DCB可减弱这些化合物诱导的细胞毒性,这表明JA、JB、JC和JD通过半胱天冬酶依赖性途径诱导凋亡。JA和JD抑制了核因子-κB的活性,核因子-κB是抗凋亡因子的转录因子。因此,这些新型对映贝壳杉烯型二萜类化合物中的一些可能是有前途的抗肿瘤药物候选物。